アブストラクト
| Title | 抗体製剤の特徴とその使い分け |
|---|---|
| Subtitle | 特集 潰瘍性大腸炎内科診療の新時代 |
| Authors | 深田憲将*, 長沼誠* |
| Authors (kana) | |
| Organization | *関西医科大学附属病院消化器肝臓内科 |
| Journal | 医学と薬学 |
| Volume | 79 |
| Number | 11 |
| Page | 1485-1491 |
| Year/Month | 2022 / 11 |
| Article | 報告 |
| Publisher | 自然科学社 |
| Abstract | 「はじめに」潰瘍性大腸炎(ulcerative colitis: UC)は慢性に炎症を来し, 再燃と寛解を繰り返す炎症性腸疾患である. 近年さまざまな新規治療薬について有用性が報告され, 長期にわたり緩解維持できる症例も増えてきた. 新規治療薬の中でも大きな役割を果たしているのは, 抗TNF-α抗体製剤に代表される, 抗体製剤である. 2002年にクローン病(Crohn's disease: CD)に抗TNF-α抗体製剤であるインフリキシマブ(Infliximab: IFX)を使用できるようになり, 高い治療効果が明らかとなり, 炎症性腸疾患(Inflammatory bowel disease: IBD)の治療に大きな変革をもたらし, 新たな抗体製剤, 分子標的薬の開発とその臨床応用を加速した. 本稿では現在UCに対して保険適用されている抗体製剤の特徴について解説する. 「I 難治性UCとは」UCの難治例の定義は, プレドニゾロン(prednisolone: PSL)1〜1.5mg/kg/日を1〜2週間投与しても効果がないステロイド抵抗例と, PSL投与し症状改善するも漸減中に症状再燃するステロイド依存例, またはステロイド以外の厳密な内科治療下にありながら頻回に再燃を繰り返す, あるいは慢性持続型を呈するものとされている. |
| Practice | 医学総合 |
| Keywords | 潰瘍性大腸炎, 生物学的製剤, 抗TNFα抗体製剤, α4接着分子阻害剤, 抗IL12/23抗体製剤 |
- 全文ダウンロード： 従量制、基本料金制の方共に913円(税込) です。
参考文献
- 1) Levin AD, Wildenberg ME, van den Brink GR: Mechanism of Action of Anti-TNF Therapy in Inflammatory Bowel Disease. J Crohns Colitis 10:989-997, 2016.
- 2) Rutgeerts P, Sandborn WJ, Feagan BG, et al: Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med 353:2462-2476, 2005.
- 3) Stidham RW, Lee TC, Higgins PD, et al: Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis. Alimentary Aliment Pharmacol Ther 39:660-671, 2014.
- 4) 厚生労働科学研究費補助金 難治性疾患等政策研究事業「難治性炎症性腸管障害に関する調査研究」(久松班)令和3年度分担研究報告書:潰瘍性大腸炎・クローン病 診断基準・治療指針 令和3年度改訂版,令和4年3月, 2022.
- 5) Brandse JF, van den Brink GR, Wildenberg ME, et al: Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis. Gastroenterology 149:350-355.e2, 2015.
残りの18件を表示する
- 6) Sandborn WJ, van Assche G, Reinisch W, et al: Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis. Gastroenterology 142:257-265.e1-3, 2012.
- 7) Reinisch W, Sandborn WJ, Hommes DW, et al: Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 60:780-787, 2011.
- 8) Sandborn WJ, Feagan BG, Marano C, et al: Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 146:85-95;quiz e14-15, 2014.
- 9) Sandborn WJ, Feagan BG, Marano C, et al: Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 146:96-109.e1, 2014.
- 10) Miyasaka M, Tanaka T: Lymphocyte trafficking across high endothelial venules: dogmas and enigmas. Nat Rev Immunol 4:360-370, 2004.
- 11) Feagan BG, Rutgeerts P, Sands BE, et al: Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med 369:699-710, 2013.
- 12) Sugiura T, Kageyama S, Andou A, et al: Oral treatment with a novel small molecule alpha 4 integrin antagonist, AJM300, prevents the development of experimental colitis in mice. J Crohns Colitis 7:e533-542, 2013.
- 13) Van Assche G, Van Ranst M, Sciot R, et al: Progressive Multifocal Leukoencephalopathy after Natalizumab Therapy for Crohn's Disease. N Engl J Med 353:362-368, 2005.
- 14) Trinchieri G: Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3:133-146, 2003.
- 15) Pirhonen J, Matikainen S, Julkunen I: Regulation of Virus-Induced IL-12 and IL-23 Expression in Human Macrophages. J Immunol 169:5673-5678, 2002.
- 16) Wilson NJ, Boniface K, Chan JR, et al: Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 8:950-957, 2007.
- 17) Friedrich M, Pohin M, Powrie F: Cytokine Networks in the Pathophysiology of Inflammatory Bowel Disease. Immunity 50:992-1006, 2019.
- 18) Sands BE, Sandborn WJ, Panaccione R, et al: Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med 381:1201-1214, 2019.
- 19) Sandborn WJ, Su C, Sands BE, et al: Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med 376:1723-1736, 2017.
- 20) Feagan BG, Danese S, Loftus EV Jr, et al: Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. Lancet 397:2372-2384, 2021.
- 21) Matsuoka K, Watanabe M, Ohmori T, et al: AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Gastroenterol Hepatol 7:648-657, 2022.
- 22) Lasa JS, Olivera PA, Danese S, et al: Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol 7:161-170, 2022.
- 23) D'Amico F, Magro F, Peyrin-Biroulet L, et al: Positioning Filgotinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis. Journal of Crohn's and Colitis 16:835-844, 2022.
